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Abstract
Background: In patients with non-valvular atrial fibrillation (NVAF) at high risk for stroke guidelines consistently
recommend long-term oral anticoagulation (OAC) with a vitamin K antagonist. However recommendations remain
ambiguous in respect to the precise OAC initiation regimens. Based on the clinical observation, that the initiation
of OAC for NVAF varies considerably in daily practice, we aimed to assess the current practice in Switzerland.
Methods: Cross-sectional survey of randomly selected general practitioners, internists and cardiologists from
different health care settings in an urban Swiss region that covers 1.4 million inhabitants. The main outcome
measures were the preferred antithrombotic initiation regimen and long-term treatment in patients with newly
diagnosed NVAF at high risk for stroke.
Results: We received 226 out of 388 (58.2%) surveys. Compared to physicians working in a hospital setting (33.6%
of respondents) physicians in ambulatory care reported more years of experience and claimed lower-use (never or
seldom) of guidelines in general (47.6 vs. 12.2%). Regarding long-term thromboembolic prophylaxis 93.7% of all
responders followed current recommendation by choosing an OAC. When focussing on guideline-consistent
correct OAC initiation (either low-dose initial OAC or a combination of LMWH and OAC) adherence dropped to
60.6% with hospital physicians demonstrating a significantly higher use of guideline-conform OAC regimens (79.7
vs. 51.0%). Medical speciality in non-hospital physicians was not related to correct guideline-use. Hospital setting
remained independently associated with a guideline-conform OAC initiation regimen (OR 2.8, p = 0.023) when
controlled for medical speciality, physicians’ characteristics and clinical experience. Problems when starting an
anticoagulation treatment were seldom reported (never or seldom accounting for 94.1% of all responses).
Conclusions: The guideline adherence with respect to OAC initiation regimens in NVAF was significantly lower
when compared to long-term treatment and health care setting rather than medical speciality explained guideline-
conform OAC initiation. The majority of the physicians did not consider the initiation of anticoagulation to be a
major obstacle in outpatient care.
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Background
Even though actual guidelines provide clear-cut recom-
mendations regarding the long-term stroke prophylaxis
in non-valvular atrial fibrillation (NVAF), they tend to
remain somewhat ambiguous with respect to the initia-
tion regimens for oral anticoagulation (OAC) [1,2]. Sev-
eral guidelines allow initiation with low-dose coumarins
alone in patients where no immediate anticoagulation
effect is warranted [1,3,4]. Nevertheless, in clinical prac-
tice many physicians in Switzerland still tend to a con-
comitant use of a low-molecular-weight heparin
(LMWH) when starting an anticoagulation treatment.
This approach takes into consideration that there is a
transient hypercoagulable state after starting a coumarin
therapy, with the level of the vitamin K-dependent
endogenous anticoagulation factor protein C dropping
rapidly compared to the prothrombogenic Factors (e.g.
IX, X and prothrombin) which leads to a transient pro-
coagulant/anticoagulant imbalance that might in turn
trigger thrombotic occlusion of small vessels followed by
necrosis (coumarine necrosis) [5]. The incidence of cou-
marine necrosis is not known, but is believed to range
from 0.01 to 0.1% [6]. It is a serious clinical condition
leading to therapeutic problems and often requiring sur-
gical intervention. On the other hand there is an
increased risk for bleeding complications in patients
simultaneously treated with LMWH and OAC and some
patients report practical problems with the administra-
tion of LMWH. Moreover, there have been concerns
about LMWH-induced skin necrosis and LMWH-
induced thrombocytopenia [7]. Based on the clinical
observation, that the initiation regimens for OAC in
outpatients with NVAF vary considerably, we conducted
a survey aimed to assess current treatment practice in
Switzerland. The purpose of our study was to assess the
current practice regarding the initiation of OAC for
NVAF in Switzerland, to determine the variables that
influence guideline consistent treatment and to inquire
whether initiation of anticoagulation is generally consid-
ered a clinical problem, as the latter might have an
impact on the choice of e.g. a novel antithrombotic
drug.
Methods
Study population
In 2009 we conducted a vignette-based survey on the
initiation of oral anticoagulation with a postal question-
naire sent to selected physicians with various specialities
in the canton of Zurich, Switzerland, a region that cov-
ers 1.4 million inhabitants. The study population was
selected from physician databases provided by the local
medical societies. The questionnaire was sent to a total
of 388 physicians consisting of a random sample of
general practitioners (n = 106), a random sample of the
internists working in a medical practice (n = 93), as well
as all the senior physicians working in a hospital depart-
ment for internal medicine (n = 87) and all the cardiolo-
gists (n = 102). A postal reminder was sent 6 weeks
after the initial questionnaire. The survey was based on
voluntary participation. No financial incentives were
provided by the investigators. Hence, no formal
informed consent was obtained from the participating
physicians. No ethical approval is required for this type
of study.
Study design
We performed a cross-sectional vignette-based survey
targeting 4 major objectives: to determine current antic-
oagulation regimens in out-patients with non-valvular
atrial fibrillation (NVAF), to determine the prevalence of
guideline conform initiation of oral anticoagulation
(OAC), to evaluate possible determinants (physician
characteristics, health care setting) of guideline conform
OAC regimens and to determine, whether physicians
consider initiation of OAC to be a problem in patient
care. The vignette described an outpatient with non-
valvular atrial fibrillation at high-risk for stroke
(CHADS2-score ≥ 2) requiring long-term OAC treat-
ment (Appendix)
Measurements
A guideline conform initiation of anticoagulation was
defined based on current recommendations as (A) start-
ing with a low dose regimen of a vitamin K antagonist
(VKA) or (B) the use of a VKA loading dose combined
with low-molecular-weight heparin (LMWH) in a thera-
peutic dose. Physician characteristics and medical
experience were assessed as follow: Demographics (age,
sex), medical speciality (general practitioner, internist,
cardiologist), practice setting (non-hospital vs. hospital
setting), medical experience including the case load of
NVAF in the previous 6 months and experienced
adverse events related to the OAC initiation (e.g. bleed-
ing, thromboembolism, skin necrosis). The frequency of
using guidelines in general was additionally assessed
semi-quantitatively (e.g. rarely, often, always).
Analysis
Categorical data are presented as frequencies. Chi-
square statistics were used to assess crude associations
between physicians’ characteristics and a guideline con-
form OAC initiation regimen and long-term OAC use,
respectively. To further investigate the independent rela-
tionship between a guideline conform OAC use and the
health care setting (e.g. hospital setting vs. ambulatory
care) multiple logistic regression analysis was applied.
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Results
Of the 388 questionnaires a total of 226 (58.2%) were
returned and could be further analyzed. Responding
rates between the various specialists in ambulatory care
and hospital physicians ranged between 47% for general
practitioners (GP) and 65% for general internists (GI).
Out of the 226 respondents the distribution of medical
speciality was as followed: 56 (24.8%) primary care phy-
sicians, 120 (53.1%) general internists, and 50 (22.1%)
cardiologists (CA). Seventy six (33.6%) out of the 226
physicians worked in hospital care. Most of the hospital
physicians were specialist in internal medicine (72.4%),
which explained the overall high proportion of general
internists with the remaining being cardiologists (25%)
and general practitioners (2.6%).
Physicians’ characteristics according to medical speci-
ality and health care setting are listed in Table 1. Of the
total study sample the majority of the physicians were
men (79.2%), however the proportion of men signifi-
cantly varied across specialities and working setting.
Overall significantly less men were working in the hos-
pital setting compared to the ambulatory care setting
and the proportion of men was higher among GP’s and
cardiologists compared to general internists in ambula-
tory care. The vast majority of the responders (84.9%)
reported at least 10 years of job experience with an
overall professional experience that was higher in
physicians working in ambulatory care compared to hos-
pital physicians. However the case load of NVAF
patients seen in the previous 6 months was higher in
hospitalists compared to GP’s and general internists in
ambulatory care. In ambulatory care physicians the pro-
portion of respondents who had a NVAF case load of
more than 5 patients within the past 6 months was sig-
nificantly higher in cardiologists compared to their col-
leagues in primary care and internal medicine. Overall
the proportion of ambulatory care physicians (GP, IM,
CA) who reported a frequent (often or always) use of
guidelines was lower compared to hospitalists (53.0 vs.
86.7%, p < 0.05). However reported guideline use signifi-
cantly differed across physicians’ speciality in ambula-
tory care with cardiologist using guidelines more
regularly (90.3% always or often), followed by internists
(53.8%), and GP’s (29.6%).
Hospitalists reported significantly more adverse events
due to OAC compared to the various specialists working
in an ambulatory setting (65.8 vs. 32.0%) (p < 0.05)
(Table 1). Thromboembolism was the most prevalent
adverse event reported followed by bleeding complica-
tions and skin necrosis due to OAC (Table 1).
Responses to the NVAF case vignette with regard to
the OAC initiation regimens as well as to the guideline
adherence are listed in detail in Table 2. The OAC
initiation regimens significantly differed between the
Table 1 Physicians’ characteristics, clinical practice and experience according to speciality and health care setting
All
N = 226
Ambulatory care
N = 150 (66.4%)
Hospital care
N = 76 (33.6%)
GP (N = 54) IM (N = 65) CA (N = 31)
Male N (%) 179 (79.2) 50 (92.6) 49 (75.4)# 27 (87.1) 53 (69.7)*
Experience N (%)
- 5-10 years 36 (15.1) 1 (1.9) 3 (4.6) 0 (0) 31 (40.8)
- 10-15 years 40 (16.8) 11 (20.4) 9 (13.9) 7 (23.3) 12 (15.8)
- > 15 years 162 (68.1) 42 (77.7) 53 (81.5) 23 (76.7) 33 (43.4)*
Case load (6 months)
- none 13 (5.4) 4 (7.4) 7 (10.8) 0 (0) 2 (2.6)
- 1 - 5 139 (57.7) 44 (81.5) 48 (73.9) 11 (35.5) 28 (36.8)
- > 5 89 (36.9) 6 (11.1) 10 (15.3) 20 (64.5)§ 46 (60.5)*
Use of Guidelines
- Rarely 81 (36) 38 (70.4) 30 (46.2) 3 (9.7) 10 (13.3)
- often 108 (48) 14 (25.9) 29 (44.6) 15 (48.4) 50 (66.7)
- always 36 (16) 2 (3.7) 6 (9.2)¥ 13 (41.9)§ 15 (20.0)*
Adverse events during OAC initiation
- reported N (% of physicians) 98 (43.4) 11 (20.4) 27 (41.5) 10 (32.3) 50 (65.8)**
- thromboembolism 52 (53.1) 6 (54.5) 17 (63.0) 10 (100.0) 19 (38.0)
- bleeding 48 (49.0) 2 (18.2) 5 (18.5) 2 (20.0) 39 (78.0)
- skin necrosis 31 (31.6) 3 (27.3) 14 (51.9) 0 (0) 14 (28.0)
*p < 0.05 vs. ambulatory care setting (GP, IM, CA); #p < 0.05 vs. GP and vs. CA; §p < 0.05 vs. GP and vs. IM; ¥p < 0.05 vs. GP; ** 98 out of the 226 participants
(43.4%) reported a total of 131 adverse events, due to multiple responses the percentage sum exceeds 100%, physicians in the hospital setting reported
significantly more adverse events compared to physicians in ambulatory care (p < 0.05)
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ambulatory and the hospital care setting (p < 0.001). A
guideline conform OAC initiation regimen (either low-
dose initial OAC or a combination of LMWH and
OAC) was found in 60.6% of the whole sample. A cor-
rect adherence was more frequently observed in hospi-
talists compared to physicians in ambulatory care (79.7
vs. 51.0%) (p < 0.001). This difference between the two
health care settings persists in the subgroups of cardiol-
ogists and general internists. Cardiologists and general
internists working in the hospital setting reported a cor-
rect OAC initiation regimen in 89% and 76%, respec-
tively, which was significantly higher compared to their
counterparts in ambulatory care with 58.1% and 53.1%,
respectively (p < 0.05 for both comparisons). However,
adherence to a guideline conform OAC initiation regi-
men did not differ across physicians’ specialities in
ambulatory care (p = 0.43). The reported adherence to a
long-term OAC regimen in the whole sample was gen-
erally high (93.7%). Again, there was a statistically signif-
icant difference between hospitalists (98.7%) and
physicians in ambulatory care (91.2%) (p = 0.038). No
difference across physicians’ specialities in ambulatory
care has been observed with regard to long-term OAC
use (p = 0.096).
Results of the multiple logistic regression analysis to
further assess the independent association between
OAC adherence and the health care setting are pre-
sented in Table 3 and 4. The hospital setting remained
significantly associated with a higher guideline conform
OAC initiation regimen when controlled for potential
confounders (Table 3). This relationship has not been
observed anymore for the long-term OAC regimen in
the multivariable analysis (Table 4).
In the whole study sample problems when starting an
anticoagulation treatment were seldom reported (never
or seldom accounting for 94.1% of all responses). The
cumulative prevalence of physicians reporting to often
or always encounter problems related to the OAC initia-
tion was significantly higher in the hospital setting
(9.7%) compared to physicians in the ambulatory care
setting (4.0%) (p for difference < 0.001).
Table 2 OAC initiation regimens and guideline adherence according to speciality and health care setting
All Ambulatory care Hospital care
GP IM CA
OAC initiation regimen N (%) 221 (100) 52 (23.5) 64 (29.0) 31 (14) 74 (33.5)*
- OAC alone loading dose 39 (17.7) 9 (17.3) 14 (21.9) 7 (22.6) 9 (12.2)
- OAC alone 30 (13.6) 5 (9.6) 3 (4.7) 2 (6.5) 20 (27.1)
- OAC + LMWH prophylactic dose 34 (15.4) 13 (25.0) 10 (15.6) 6 (19.4) 5 (6.8)
- OAC + LMWH therapeutic dose 104 (47.1) 18 (34.6) 31 (48.4) 16 (51.6) 39 (52.7)
- OAC + Aspirin 4 (1.8) 2 (3.9) 2 (3.1) 0 (0) 0 (0)
- Aspirin alone 5 (2.3) 4 (7.7) 1 (1.6) 0 (0) 0 (0)
- Various 5 (2.3) 1 (1.9) 3 (4.7) 0 (0) 1 (1.4)
Guideline conform OAC initiation (%) 134 (60.6) 23 (44.2) 34 (53.1) 18 (58.19) 59 (79.7)*
Long-term OAC regimen (%) 207 (93.7) 45 (86.5) 58 (90.6) 31 (100) 73 (98.7)*
Total N = 221, 5 respondents were excluded due to multiple responses thus a sound classification of the OAC initiation regimen was not possible; * p < 0.05 vs.
ambulatory care setting (GP, IM, CA)
Table 3 Adjusted associations between a guideline
conform OAC initiation in relation to the health care
setting
OR 95%-CI p-value
Model 1 (N = 221):
Ambulatory care 1.00
Hospital care 3.5 1.7-7.0 < 0.001
Model 2 (N = 219):
Ambulatory care 1.00
Hospital care 2.8 1.2-6.9 0.023
Model 1: Adjusted association between guideline a conform OAC initiation
and the health care setting controlled for physicians’ speciality (GP, internist,
cardiologist)
Model 2: Model 1 in addition adjusted for physicians’ characteristics (gender,
general use of guidelines) and clinical experience (adverse events, years of
experience, NVAF cases last 6 months)
Table 4 Adjusted associations between a long-term OAC
regimen in relation to the health care setting
OR 95%-CI p-value
Model 1 (N = 221):
Ambulatory care 1.00
Hospital care 5.8 0.7-49.2 0.10
Model 2 (N = 219):
Ambulatory care 1.00
Hospital care 4.8 0.4-59.5 0.22
Model 1: Adjusted association between a long-term OAC regimen and the
health care setting controlled for physicians’ speciality (GP, internist,
cardiologist)
Model 2: Model 1 in addition adjusted for physicians’ characteristics (gender,
general use of guidelines) and clinical experience (adverse events, years of
experience, NVAF cases last 6 months)
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Discussion
The data of our survey confirm the expected variability
in guideline adherence in respect to initiation of antic-
oagulation in non-valvular atrial fibrillation (NVAF),
with health care setting rather than medical speciality
being associated with a recommendation consistent
treatment. The majority of the physicians does not con-
sider the initiation of OAC to be a major problem in
patient care.
The factors commonly influencing guideline adher-
ence of physicians are well known and consist in (i) the
quality of the data leading to the actual treatment
recommendations, (ii) familiarity with the recommenda-
tions (iii) the physicians agreement with the recommen-
dations, (iv) the expected impact of a therapeutic
measure on the disease outcome (v) the patient popula-
tion and (vi) organisational factors such as workload
and convenience of the recommendations) [8,9]. We dis-
cuss the results of our survey based on these key factors.
Quality of data: In NVAF there is an imbalance in the
quality of the data leading to the actual treatment
recommendations. While there are well-established scor-
ing systems assessing the risk for stroke in NVAF (e.g.
CHA2DS2-VASc and CHADS2) and an effective pro-
phylaxis with the vitamin K antagonists (VKA) leading
to a class IA recommendation for long-term VKA pro-
phylaxis in high-risk patients with NVAF, data regarding
the optimal initiation of OAC is sparse [1,10-16]. E.g.
there is no prospective trial comparing an OAC initia-
tion regimen with and without concurrent heparin or
low-molecular-weight heparin (LMWH) use. In addition,
there is a lack of data on the incidence of heparin- and
warfarin-induced skin necrosis and the occurrence of
stroke when commencing an OAC prophylaxis, which
leads to considerable uncertainty about the need for
concurrent OAC and Heparin or LMWH. Therefore,
recommendations are less stringent for OAC initiation
but nevertheless, ACCP 2008 guidelines as well as
BCSH 2005 guidelines do allow a low-dose VKA com-
mencement without concurrent heparin or LMWH if
no immediate anticoagulation effect is warranted [3,4].
This difference in the quality of scientific data might be
reflected by our study results which confirm a high the-
oretical adherence to guidelines in respect to long-term
OAC (93.7%) whereas a correct initiation regimen
defined as choosing either a low-dose VKA scheme or
adding LMWH to a VKA loading dose scheme was cho-
sen by only 60.6% of all participants. We did not find a
difference in the adherence of long-term OAC across
medical specialities. This is in line with McCrory and
coworkers who addressed physicians attitudes on long-
term OAC for stroke prophylaxis in different clinical
scenarios by means of a case-vignette which revealed no
difference between primary care physicians, cardiologists
and neurologists [17]. However we are not aware of stu-
dies that focused on the initiation of OAC in NVAF or
the impact of the health care setting on this issue.
Familiarity and agreement with the recommendations:
Another factor influencing guideline adherence is the
knowledge of the recommendations themselves. An eur-
opean study found, that cardiologists show a higher
familiarity with heart failure guidelines when compared
to internists, geriatricians, and primary care physicians
[18]. Our data is more conflicting as 90.3% of all cardi-
ologists working in outpatient care reported to use
guidelines for decision making but only 58.2% actually
chose a guideline conform OAC initiation regimen.
Moreover, our data does not show a significant differ-
ence between the various medical specialities with
regard to guideline-consistent anticoagulation for stroke
prophylaxis in NVAF. It is known from the literature
that practicing physicians have an attitudinalbehavioral
discordance concerning their positive perception of clin-
ical practice guidelines and the implementation of these
guidelines into their own clinical practice [19]. Never-
theless, we can only hypothesize on the reasons for this
imbalance in our cardiologist group: First, even though
the cardiologists may usually be familiar with many
guidelines, this might not be the case regarding this par-
ticular topic. Second, the physician might disagree with
the guidelines and third, there might be a lack of out-
come expectancy when adhering to the guidelines.
Outcome expectancy and patient selection: The
hypothesis that the outcome expectancy and the patient
selection might play an important role in clinical practice
is supported by our data reporting a significant difference
in guideline consistent behaviour, mainly depending on
the health-care setting with hospital physicians showing a
higher degree of guideline adherence than doctors in out-
patient care. Patients with NVAF who have to be referred
to a hospital are either relatively fit but will undergo car-
dioversion within 48 hours of onset or, which is more
likely, represent a different patient subset with comorbid-
ities or an acute condition leading to hospital admission
[20]. The latter has an impact on OAC, as e.g. anticoagu-
lation dependent skin necrosis is known to only rarely
occur in otherwise healthy outpatients treated for NVAF
but is mainly observed in more severely ill hospitalized
patients with comorbidities [6,21-23]. Hence, doctors
working in a hospital setting are exposed to a different
patient population and more likely to be confronted with
adverse events, an experience which might constrain
them to a more guideline stringent behaviour [8]. As a
matter of fact, hospital physicians in our study reported a
significantly higher number of adverse events during the
initial phase of a OAC treatment. In contrast, physicians
working in a private practice claim to observe adverse
events only in a minority of cases which might lessen the
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need for guidelines as they are not believed to signifi-
cantly influence disease outcome.
The generally low use of guidelines in the general
practitioner fraction is also noteworthy. We hypothesize
that beside the difficulty in keeping up with a high level
of knowledge in a large and heterogenous medical field,
this might also be due to the high prevalence of multi-
morbide patients seen in family practice [24]. Physicians
caring for multimorbide patients might consider it less
reasonable to implement a therapeutical strategy solely
based on the summation of single-disease recommenda-
tions as this will be far to comprehensive and might
even proof to be harmful in this context [25,26].
Limitations
First, the design of our study is a limitating factor as all
observational studies always lack the power to proof
causality. Second, even though our survey shows a high
return rate of 58% and is therefore clearly representative
for the clinical practice in an urban area in Switzerland,
its results might not apply for other countries as e.g. in
Switzerland the VKA of choice for patients with NVAF
is phrenprocoumon which has a much longer elimina-
tion half life when compared to warfarin (140 vs. 40
hours). Most international trials are based on a VKA
treatment with warfarin and even though the results
might not differ substantially from a treatment with
other VKAs, the conclusions obtained from a study with
warfarin can, strictly spoken, not be translated to other
treatment modalities. Third, a survey always assesses a
theoretical adherence to therapies or treatment recom-
mendations and despite the fact, that the majority of
doctors might be familiar with current guidelines, they
might not consequently translate them into clinical
practice. In an observational study conducted in Basel,
Switzerland, 31% of all patients with atrial fibrillation
who qualified for an oral anticoagulation did not receive
a VKA [27]. This finding is supported by data from
many different regions worldwide [28].
Conclusion
Our present study shows how physicians intend to start
stroke prophylaxis in outpatients with NVAF in an
urban region in Switzerland. Whilst the theoretical
knowledge of the correct long-term treatment for these
patients is excellent, compliance to guidelines with
respect to the initiation of anticoagulation is not. There
is a difference in guideline adherence based on the clini-
cal setting, with hospital physicians showing a better
guideline adherence when compared to their colleagues
in outpatient care. Further studies are needed to address
this issue and detect possible causes. We hypothesize
that patient selection, outcome expectancy, and familiar-
ity with guidelines might account for a good part of this
difference. However, as with the introduction of any
practice guideline, physicians need to be convinced that
there exists compelling evidence from well-controlled
clinical trials to justify implementation of these recom-
mendations to the individual patient.
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